Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung

E. S. Casper, Richard J. Gralla

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Because of the reported activity of the lipid-soluble nitrosoureas in non-small cell carcinoma of the lung, a phase II trial of chlorozotocin in this disease was undertaken. Thirty-five patients were enlisted in the study between March 1977 and March 1978. Two PRs were noted in the 30 (7%) evaluable patients. At 95% confidence limits, the predicted true response rate is 2%-18%. The authors conclude that chlorozotocin, when given in the present dose and schedule, is only a marginally effective agent in the treatment of non-small cell carcinoma of the lung, and that it offers no therapeutic advantage over the nitrosoureas currently used in the treatment of this disease.

Original languageEnglish (US)
Pages (from-to)549-550
Number of pages2
JournalCancer Treatment Reports
Volume63
Issue number4
StatePublished - 1979
Externally publishedYes

Fingerprint

chlorozotocin
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Therapeutics
Lipids

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung. / Casper, E. S.; Gralla, Richard J.

In: Cancer Treatment Reports, Vol. 63, No. 4, 1979, p. 549-550.

Research output: Contribution to journalArticle

@article{2596c31a1edc46aebaa1a272a533a9cc,
title = "Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung",
abstract = "Because of the reported activity of the lipid-soluble nitrosoureas in non-small cell carcinoma of the lung, a phase II trial of chlorozotocin in this disease was undertaken. Thirty-five patients were enlisted in the study between March 1977 and March 1978. Two PRs were noted in the 30 (7{\%}) evaluable patients. At 95{\%} confidence limits, the predicted true response rate is 2{\%}-18{\%}. The authors conclude that chlorozotocin, when given in the present dose and schedule, is only a marginally effective agent in the treatment of non-small cell carcinoma of the lung, and that it offers no therapeutic advantage over the nitrosoureas currently used in the treatment of this disease.",
author = "Casper, {E. S.} and Gralla, {Richard J.}",
year = "1979",
language = "English (US)",
volume = "63",
pages = "549--550",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung

AU - Casper, E. S.

AU - Gralla, Richard J.

PY - 1979

Y1 - 1979

N2 - Because of the reported activity of the lipid-soluble nitrosoureas in non-small cell carcinoma of the lung, a phase II trial of chlorozotocin in this disease was undertaken. Thirty-five patients were enlisted in the study between March 1977 and March 1978. Two PRs were noted in the 30 (7%) evaluable patients. At 95% confidence limits, the predicted true response rate is 2%-18%. The authors conclude that chlorozotocin, when given in the present dose and schedule, is only a marginally effective agent in the treatment of non-small cell carcinoma of the lung, and that it offers no therapeutic advantage over the nitrosoureas currently used in the treatment of this disease.

AB - Because of the reported activity of the lipid-soluble nitrosoureas in non-small cell carcinoma of the lung, a phase II trial of chlorozotocin in this disease was undertaken. Thirty-five patients were enlisted in the study between March 1977 and March 1978. Two PRs were noted in the 30 (7%) evaluable patients. At 95% confidence limits, the predicted true response rate is 2%-18%. The authors conclude that chlorozotocin, when given in the present dose and schedule, is only a marginally effective agent in the treatment of non-small cell carcinoma of the lung, and that it offers no therapeutic advantage over the nitrosoureas currently used in the treatment of this disease.

UR - http://www.scopus.com/inward/record.url?scp=0018763033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018763033&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 549

EP - 550

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -